NCT01577758View on ClinicalTrials.gov

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Advanced Gastrointestinal Malignancies
Interventions
DRUG

MLN0264

MLN0264 30-minute infusion on Day 1 of each treatment cycle

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01577758 - Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C | Biotech Hunter | Biotech Hunter